Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
91 hedge funds and large institutions have $169M invested in Poseida Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 24 reducing their positions, and 14 closing their positions.
324% more call options, than puts
Call options by funds: $920K | Put options by funds: $217K
46% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 24
11% more capital invested
Capital invested by funds: $152M → $169M (+$16.3M)
7.37% more ownership
Funds ownership: 47.42% → 54.79% (+7.4%)
0% more funds holding
Funds holding: 91 → 91 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$14.9M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$2.45M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.31M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.13M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$454K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$402K |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$383K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$364K |
PSTX Hedge Fund Activity: Q1 2024 in Review
91 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q1 2024, worth a combined $169M — up 11% from $152M a quarter earlier.
Fund positioning in PSTX was balanced in Q1 2024: 14 funds opened new positions, 14 closed out, 35 added to existing stakes and 24 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $14.9M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.13M sold.
- 91 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $169M of Poseida Therapeutics, Inc. Common Stock stock for Q1 2024, up 11% quarter-over-quarter.
- 14 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q1 2024 and 14 closed out, a net change of 0 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q1 2024 was Boxer Capital, an estimated $14.9M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q1 2024 was Point72 Asset Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q1 2024.